CoChat

The Future of Anti-Amyloid Trials

Open access
Aisen, P.S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D.J., Sims, J., Sperling, R.A., Vellas, B. · 2020 · The Journal of Prevention of Alzheimer's Disease
Cited by 59

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer's disease (AD) has had a major impact on the AD clinical research enterprise. However, positive signals in recent studies have reinvigorated support for the amyloid hypothesis and amyloid-targeting strategies. In December 2019, the EU-US Clinical Trials on Alzheimer's Disease (CTAD) Task Force met to share learnings from these studies in order to inform future trials and promote the development of effective AD treatments. Critical factors that have emerged in studies of anti-amyloid monoclonal antibody therapies include developing a better understanding of the specific amyloid species targeted by different antibodies, advancing our insight into the mechanism by which those antibodies may reduce pathology, implementing more comprehensive repertoires of biomarkers into trials, and identifying appropriate doses. Studies suggest that Amyloid-Related Imaging Abnormalities - effusion type (ARIA-E) are a manageable safety concern and that caution should be exercised before terminating studies based on interim analyses. The Task Force concluded that opportunities for developing effective treatments include developing new biomarkers, intervening in early stages of disease, and use of combination therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14283/jpad.2020.24

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 12

  1. Wessels, 2019, Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials, JAMA Neurol
  2. Cummings, 2018, ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease, Neurology, 90, e1889, 10.1212/WNL.0000000000005550 · DOI · Paper page
  3. Farlow, 2012, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement, 8, 261, 10.1016/j.jalz.2011.09.224 · DOI · Paper page
  4. Willis, 2018, Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia, Alzheimers Dement (N Y), 4, 652, 10.1016/j.trci.2018.10.001 · DOI · Paper page
  5. Doody, 2020, The role of futility analyses in AD clinical trials, J Prev Alz Dis, 7
  6. Aisen, 2019, Editorial: Failure After Failure. What Next in AD Drug Development?, J Prev Alzheimers Dis, 6, 150, 10.14283/jpad.2019.23 · DOI
  7. Zetterberg, 2019, Blood-based molecular biomarkers for Alzheimer's disease, Molecular Brain, 12, 26, 10.1186/s13041-019-0448-1 · DOI · Paper page
  8. Gauthier, 2019, Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force, J Prev Alzheimers Dis, 6, 164, 10.14283/jpad.2019.12 · DOI · Paper page
  9. Cummings, 2019, Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force, J Prev Alzheimers Dis, 6, 157, 10.14283/jpad.2019.14 · DOI · Paper page
  10. Harrison, 2019, Tau deposition is associated with functional isolation of the hippocampus in aging, Nat Commun, 10, 4900, 10.1038/s41467-019-12921-z · DOI · Paper page
  11. Chen, 2019, Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease, Alzheimers Dement, 15, 487, 10.1016/j.jalz.2018.09.010 · DOI · Paper page
  12. Aisen, 2018, What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force, J Prev Alzheimers Dis, 5, 171, 10.14283/jpad.2018.23 · DOI

Cited by

See all 59

Metadata

Authors
Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., & Vellas, B.
Venue
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Published
2020-06
Volume
7
Issue
3
Pages
146-151
ISSN
2274-5807 (ISSN-L)
OpenAlex
W3026315764
Cited by
59
References
17
FWCI
5.41
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.